Background The stratification of outpatients on chemotherapy for breast, colorectal, lung,
and ovarian cancers at risk of venous thromboembolism (VTE) remains an unmet clinical …

In ambulatory patients with solid cancer, routine thromboprophylaxis to prevent venous
thromboembolism is not recommended. Several risk prediction scores to identify cancer …

Cancer patients are at increased risk of developing venous thromboembolism (VTE).
Guidelines recommend routine thromboprophylaxis in hospitalised acutely ill cancer …

Rates of venous thromboembolism (VTE) vary substantially between cancer patients.
Multiple clinical risk factors including primary site of cancer and systemic therapy, and …

Purpose Patients with cancer are increasingly at risk for venous thromboembolism (VTE).
Rates of VTE, however, vary markedly among patients with cancer. Design This review …

Background. Retrospective studies have suggested an association between cancer-
associated venous thromboembolism (VTE) and patient survival. We evaluated a previously …

The Khorana score is recommended for guiding primary venous thromboembolism (VTE)
prophylaxis in cancer patients, but its clinical utility overall and across cancer types remains …

Cancer-associated venous thromboembolism (VTE) has major consequences for patients,
including morbidity and risk of mortality. However, there is substantial variation in risk …

Patients with cancer are heterogeneous concerning the risk for VTE. Some solid
malignancies including pancreatic, lung, colon-rectum, ovarian, and brain cancer are …

The Asian population is thought to have a low risk of venous thromboembolism (VTE), but
the epidemiology of VTE in cancer patients remains unclear. The National Health Insurance …